Loading viewer...
earnings
Format: PDF earnings
Jubilant Pharmova's financial results presentation for Q3 FY2024 (quarter ended December 31, 2023). The company reported FY23 revenue of approximately Rs 6,300 Cr (~US$ 783 million) and operates as an integrated global pharmaceuticals and contract research organization with strengths in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, and drug discovery services.
earnings
29 Pages
Toast, Inc.
EP Energy Q2 2016 Financial and Operational Report
earningsearnings
16 Pages
EP Energy Corporation
Capital Senior Living Q1 2020 Earnings Presentation
earningsearnings
17 Pages
Capital Senior Living
TC Energy Q2 2023 Earnings Conference Call - July 28
earningsearnings
34 Pages
TC Energy Corporation
Absa Group FY18 2019 Results Presentation
earningsearnings
23 Pages
Absa Group Limited